Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

519 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.
Malighetti F, Villa M, Mauri M, Piane S, Crippa V, Crespiatico I, Cocito F, Bossi E, Steidl C, Civettini I, Scollo C, Ramazzotti D, Gambacorti-Passerini C, Piazza R, Mologni L, Aroldi A. Malighetti F, et al. Among authors: piazza r. Biomedicines. 2024 Dec 12;12(12):2819. doi: 10.3390/biomedicines12122819. Biomedicines. 2024. PMID: 39767726 Free PMC article.
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
Bossi E, Aroldi A, Brioschi FA, Steidl C, Baretta S, Renso R, Verga L, Fontana D, Sharma GG, Mologni L, Mussolin L, Piazza R, Gambacorti-Passerini C. Bossi E, et al. Among authors: piazza r. Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3. Am J Hematol. 2020. PMID: 32808682 Free article. Clinical Trial. No abstract available.
Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma.
Arosio G, Sharma GG, Villa M, Mauri M, Crespiatico I, Fontana D, Manfroni C, Mastini C, Zappa M, Magistroni V, Ceccon M, Redaelli S, Massimino L, Garbin A, Lovisa F, Mussolin L, Piazza R, Gambacorti-Passerini C, Mologni L. Arosio G, et al. Among authors: piazza r. Cancers (Basel). 2021 Sep 1;13(17):4422. doi: 10.3390/cancers13174422. Cancers (Basel). 2021. PMID: 34503232 Free PMC article.
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A, Mauri M, Ramazzotti D, Villa M, Malighetti F, Crippa V, Cocito F, Borella C, Bossi E, Steidl C, Scollo C, Voena C, Chiarle R, Mologni L, Piazza R, Gambacorti-Passerini C. Aroldi A, et al. Among authors: piazza r. J Cell Mol Med. 2023 Oct;27(20):3053-3064. doi: 10.1111/jcmm.17868. Epub 2023 Aug 31. J Cell Mol Med. 2023. PMID: 37654003 Free PMC article.
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.
Villa M, Sharma GG, Malighetti F, Mauri M, Arosio G, Cordani N, Lobello C, Larose H, Pirola A, D'Aliberti D, Massimino L, Criscuolo L, Pagani L, Chinello C, Mastini C, Fontana D, Bombelli S, Meneveri R, Lovisa F, Mussolin L, Janikova A, Pospíšilová Š, Turner SD, Inghirami G, Magni F, Urso M, Pagni F, Ramazzotti D, Piazza R, Chiarle R, Gambacorti-Passerini C, Mologni L. Villa M, et al. Among authors: piazza r. Br J Cancer. 2024 Dec;131(11):1781-1795. doi: 10.1038/s41416-024-02881-7. Epub 2024 Oct 30. Br J Cancer. 2024. PMID: 39478125 Free PMC article.
How I treat newly diagnosed chronic myeloid leukemia in 2015.
Gambacorti-Passerini C, Piazza R. Gambacorti-Passerini C, et al. Among authors: piazza r. Am J Hematol. 2015 Feb;90(2):156-61. doi: 10.1002/ajh.23887. Epub 2014 Nov 24. Am J Hematol. 2015. PMID: 25370814 Free article. Review.
519 results